Ireland Could Be Missing Out On Biosimilar Savings


Ireland’s government has failed to seek out generic alternatives to expensive branded drugs, which could put the country at risk for overpaying by hundreds of millions of euros. For example, Pfizer’s rheumatoid arthritis drug Enbrel faced a biosimilar challenge when Biogen’s Benepali came to the market. But in the first several months of the new biosimilar competition, around 10,000 Enbrel packets were sold compared to only three packets of Benepali.

Read the source article at The Irish Times

About the Author

Related Posts

Leave a Reply